Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.
We are also leveraging our background in bile acid chemistry to discover and develop other compounds.
*Investigational uses and have not been approved by the FDA or any other worldwide regulatory agency. Safety and efficacy have not been established.
± Intercept has a license to develop and commercialize in the U.S. only.
OCA = obeticholic acid; PBC = primary biliary cholangitis; NASH = nonalcoholic steatohepatitis; NDA = new drug application; sAH = severe alcohol-associated hepatitis; FXR = farnesoid X receptor; FDA = Food and Drug Administration
You are now leaving Intercept Pharmaceuticals’ corporate website and entering a site intended for U.S. audiences only.
You are now leaving Intercept Pharmaceuticals’ corporate website. Intercept does not control or endorse the content of this external site.
The link you have selected will take you outside of Intercept Pharmaceuticals’ corporate website.
The site you will be entering is intended for U.S. audiences only.
If you are a healthcare provider looking for product information, visit ocalivahcp.com.
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.
Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed.
United States (US)
European Union (EU)
Canada
Israel
Switzerland
Australia
Liechtenstein
United Arab Emirates (UAE)
Exploring Racial Differences and Disparities in PBC Care